Thermo Fisher Scientific stock
Price history
+20.70% over the period1 year: from $580.13 (November 13, 2025) to $700.22 (November 13, 2026), +20.70%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $700.22 |
| October 30, 2026 | $697.00 |
| September 30, 2026 | $675.05 |
| August 31, 2026 | $617.10 |
| July 31, 2026 | $574.30 |
| June 30, 2026 | $501.36 |
| May 29, 2026 | $492.51 |
| April 30, 2026 | $478.96 |
| March 31, 2026 | $491.53 |
| February 27, 2026 | $521.11 |
| January 30, 2026 | $578.61 |
| December 31, 2025 | $579.45 |
| November 28, 2025 | $590.83 |
| November 13, 2025 | $580.13 |
At a glance
The company
Provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services
Latest results
Quarter to September 30, 2026 · EPS $6.68 (estimate $6.41)
Next event
Dividend
TickerLandia's take on Thermo Fisher Scientific
- Pricier than usual relative to earnings: P/E on the latest fiscal year 39 vs a median of 32 over its last 10 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 37 vs 36 (+1%) in a group of 10.
- Strong point: Market momentum (86/100 in its group). Weak point: Dividend (20/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−3.76% from the 52-week high
Analysts · 27 analysts
Average target$756.52+8.04% vs. price
Buy 23 · Hold 3 · Sell 1 · Strong buy
TickerLandia Fingerprint: Thermo Fisher Scientific
Compared with similar companies: very strong momentum.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage57
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 36.9 56 Forward P/E 25.2 58 Price/sales 5.48 50 Price/book 4.74 56 EV/EBITDA 24.3 66 Profitabilityaverage54
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 19.1% 61 Gross margin 41.3% 43 Net margin 14.9% 65 ROE 13.4% 61 ROA 5.2% 39 Earnings stabilityaverage52
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.8% 43 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthlow39
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +8.70% 35 Average revenue growth (3 years) −0.27% 24 Revenue growth (year over year) +9.10% 57 Financial strengthaverage41
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.75 35 Interest coverage 5.89 44 Current ratio 1.81 57 Net debt/EBITDAcounts in reverse: lower means more financial strength 2.78 26 Dividendlow20
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 9.7% 3 Consecutive dividend years 15 years 47 Dividend yield 0.3% 10 Market momentumvery strong86
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) +54.55% 96 Relative strength (3 months) +21.20% 92 1-year return +20.70% 62 Distance from 200-day average +26.08% 93 Riskaverage46
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 31.5% 56 Beta (1 year) 0.71 51 Volatility (60 days) 27.7% 32
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Thermo Fisher Scientific is pricier than in the past and in line with similar companies
On the latest fiscal year's earnings (2025), Thermo Fisher Scientific's P/E today is 39.5, above the median of its last 10 fiscal years (32.1; between 27.7 and 35.4 from 2016 to 2025). Thermo Fisher Scientific's P/E (trailing 12 months): 36.9, in line with the median of a group of 10 similar companies (36.5).
Compared with 10 similar companies
| Metric | Thermo Fisher Scientific | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 36.9 | Middle | |
| Forward P/E | 25.2 | Middle | |
| Operating margin | 19.1% | Middle | |
| ROE | 13.4% | Middle | |
| Debt/equity | 0.75 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Thermo Fisher Scientific. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$12.14B
Latest quarter · Q3 2026
Net income
$1.72B
Latest quarter · Q3 2026
Quarterly net margin
14.2%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $259.44B
- P/E
- 36.9
- EPS
- $18.96
- Volume
- 1.83M
- Daily trading
- €1.41B
- Dividend yield
- 0.26%
How Thermo Fisher Scientific is changing
All resultsRevenue grew 6.7% a year on average over the last 5 years
Operating margin fell from 18.7% to 17.4%
Profits turn into cash: free cash flow equal to 108% of net income
Returns
Thermo Fisher Scientific returns with dividends
$1,000 invested in Thermo Fisher Scientific 5 years ago, on November 15, 2021, would be worth $1,123 today with dividends reinvested: +12.32% in total, +2.35% per year. On price alone it would be $1,107 (+10.73%).
| Period | Thermo Fisher Scientific | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +5.61% | −3.12% | $1,056 |
| 6 months | +56.99% | +1.58% | $1,570 |
| Year to date | +20.84% | +10.46% | $1,208 |
| 1 year | +21.12% | +12.23% | $1,211 |
| 3 years | +58.83% | +71.41% | $1,588 |
| 5 years | +12.32% | +61.48% | $1,123 |
| 10 years | +386.61% | +249.40% | $4,866 |
Over the last 6 months it has done better than 91% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Thermo Fisher Scientific: technical analysis
Thermo Fisher Scientific is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 3.0% below its highest close since January 2, 1990 ($721.63, November 9, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 54
- Between 30 and 70
- vs 200-session average
- +26.08%
Support and resistance
Price areas where Thermo Fisher Scientific has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$700.22
- Support$645.49−7.82%2 touches, last on August 25, 2026
- Support$631.70−9.79%2 touches, last on October 8, 2026
- Support$589.42−15.82%4 touches, last on September 10, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.71
- Volatility (60 sessions, annualised)
- 27.7%
- Largest fall in the last year
- −31.45%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Thermo Fisher Scientific: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Thermo Fisher Scientific has been December: +2.76% on average, positive in 24 years out of 36. The weakest has been February: −1.45% on average, positive in 18 years out of 37. November, the current month, has been positive in 20 years out of 36 (+2.21% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.33% | +2.74% | 20 of 36 |
| February | −1.45% | −0.36% | 18 of 37 |
| March | +1.33% | +1.40% | 21 of 37 |
| April | +2.17% | +1.36% | 22 of 37 |
| May | +2.32% | +2.65% | 23 of 37 |
| June | −0.73% | −0.54% | 15 of 37 |
| July | +2.02% | +3.54% | 25 of 37 |
| August | +0.49% | +1.95% | 23 of 37 |
| September | −0.07% | +1.24% | 23 of 37 |
| October | +2.34% | +2.45% | 24 of 37 |
| November | +2.21% | +2.44% | 20 of 36 |
| December | +2.76% | +1.48% | 24 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Thermo Fisher Scientific and its competitors
Pharmaceutical and biotechnology companies, academic and government laboratories, clinical laboratories, environmental and industrial users, and hospitals make up the customer base of this group, which sells in markets around the world. Its offering spans reagents, instruments and consumables used in biological and medical research, tools for the discovery and production of drugs and vaccines, and diagnostics for infections and diseases.
- Headquarters
- Waltham, United States
- Employees
- 125,000
- Founded
- 1956
- Chief executive
- Marc Casper
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Thermo Fisher ScientificTMO | $259.44B | 19.1% | 36.9 | +56.99% |
| DanaherDHR | $163.94B | 22.0% | 38.6 | +40.38% |
| WatersWAT | $90.45B | 16.0% | 192.6 | +37.42% |
| IDEXX LaboratoriesIDXX | $55.48B | 32.5% | 47.0 | +33.21% |
| Agilent TechnologiesA | $49.04B | 24.5% | 34.3 | +54.30% |
| NateraNTRA | $46.27B | -8.5% | — | +63.37% |
Same industry or related industries, similar size. Compare Thermo Fisher Scientific with its competitors · Full profile
More on Thermo Fisher Scientific
- Thermo Fisher Scientific revenue and financials
- Thermo Fisher Scientific dividend and valuation
- Thermo Fisher Scientific stock return
- Thermo Fisher Scientific employees, headquarters and business
